Theres never any pressure just facts and, when needed, sound consultation
Curr DiabRep 20:19 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials
The dose of PYY-based compounds was escalated at day 4 from 100 nmol kg 1 to 500 nmol kg 1
Tirzepatide is a newer medication that activates both GLP-1 and GIP receptors, another gut hormone
The absence of pharmacokinetic studies, dose-response relationships, or comparative effectiveness data represents a significant evidence gap
GLP-1 can help manage weight and blood sugar, but it is far from the only option